Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
7.35
+0.13 (1.80%)
Aug 13, 2025, 4:00 PM - Market closed
Bicycle Therapeutics Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Bicycle Therapeutics stock ranges from a low of $10 to a high of $44. The average analyst price target of $22.91 forecasts a 211.70% increase in the stock price over the next year.
Price Target: $22.91 (+211.70%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bicycle Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 5 | 5 | 6 | 7 |
| Hold | 2 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 10 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $22 → $10 | Buy | Maintains | $22 → $10 | +36.05% | Aug 12, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $17 → $13 | Hold | Maintains | $17 → $13 | +76.87% | Aug 12, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $48 → $44 | Buy | Maintains | $48 → $44 | +498.64% | Aug 11, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $32 → $25 | Buy | Maintains | $32 → $25 | +240.14% | Jul 17, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $15 → $17 | Hold | Maintains | $15 → $17 | +131.29% | May 6, 2025 |
Financial Forecast
Revenue This Year
37.87M
from 35.28M
Increased by 7.35%
Revenue Next Year
35.07M
from 37.87M
Decreased by -7.39%
EPS This Year
-3.90
from -2.90
EPS Next Year
-4.57
from -3.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 57.7M | 69.3M | 144.3M | ||
| Avg | 37.9M | 35.1M | 77.6M | ||
| Low | 15.7M | n/a | 18.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.7% | 82.9% | 311.5% | ||
| Avg | 7.4% | -7.4% | 121.1% | ||
| Low | -55.6% | - | -46.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.44 | -4.28 | -2.96 | ||
| Avg | -3.90 | -4.57 | -4.05 | ||
| Low | -4.25 | -5.25 | -5.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.